10-K: Indivior's 2025 Annual Report: SUBLOCADE Drives Growth

Indivior Pharmaceuticals reports strong 2025 revenue growth driven by SUBLOCADE, alongside strategic restructuring and U.S. domestication.

Summary

• Net revenue increased 4% to $1,239 million in 2025 from $1,188 million in 2024.
• Operating income surged 594% to $262 million in 2025 from $38 million in 2024.
• Net income was $210 million in 2025, up from $7 million in 2024.
• SUBLOCADE sales grew 13% to $856 million in 2025, representing 69% of total net revenue.
• U.S. SUBLOCADE revenue increased 13% to $794 million, with 7% from dispense unit volume growth and 6% from gross-to-net adjustments.
• Sublingual & other product net revenue declined 7% to $351 million due to increased competitive activity for SUBOXONE Film.
• Discontinued marketing and promotion for PERSERIS in July 2024 and OPVEE in the third quarter of 2025.
• Recognized $127 million in restructuring charges in 2025 related to headcount reductions, real estate consolidations, asset impairments, and contract terminations.
• Completed U.S. Domestication in January 2026, becoming Indivior Pharmaceuticals, Inc., a Delaware corporation.
• Completed obligations under the Corporate Integrity Agreement (CIA) in July 2025 and the Resolution Agreement in November 2025.
• FDA approved SUBLOCADE label changes in February 2025, including a rapid initiation protocol and alternative injection sites.
• Initiated Phase 2 clinical studies for INDV-6001 (three-month LAI buprenorphine) and INDV-2000 (selective orexin-1 receptor antagonist), with results expected in the second quarter of 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, primarily driven by the strong performance of SUBLOCADE and the resolution of significant past litigation, despite challenges with older products and restructuring costs.

Positives

• Strong SUBLOCADE growth: 13% increase in net revenue to $856 million, now 69% of total revenue, demonstrating market leadership in long-acting injectables for OUD.
• Significant increase in operating income (594% to $262 million) and net income (from $7 million to $210 million), indicating improved financial performance.
• FDA approval of SUBLOCADE label changes (rapid initiation, alternative injection sites) is expected to enhance patient access and treatment flexibility.
• Completion of Corporate Integrity Agreement (CIA) obligations in July 2025 and Resolution Agreement in November 2025 reduces significant compliance burdens and legal overhangs.
• U.S. Domestication completed in January 2026, simplifying the corporate structure and reinforcing focus on the U.S. market.
• Pipeline progress with Phase 2 studies for INDV-6001 and INDV-2000, offering potential future growth drivers in OUD treatment.
• SUBLOCADE maintains broad payor access in the U.S. with over 88% of insured lives covered and a co-pay program ensuring over 95% of patients pay $0 out of pocket.
• Successful dismissal of the representative action in the U.K. shareholder claims and the U.S. shareholder class action lawsuit, reducing litigation exposure.
• Dismissal of Opiant stockholder claims and San Miguel Hospital Corp. v. Johnson & Johnson, et al. case as to Indivior.

Negatives

• Sublingual & other product net revenue declined 7% due to increased generic competition for SUBOXONE Film, with its category share falling to 14.2% in 2025 from over 50% in 2018.
• Discontinuation of marketing and promotion for PERSERIS (July 2024) and OPVEE (Q3 2025) indicates challenges in diversifying the product portfolio.
• Incurred $127 million in restructuring charges in 2025, impacting profitability in the short term.
• Expected decline in total net revenue in 2026 due to competitive pressures on SUBOXONE Film and strategic exits from certain non-U.S. markets.
• Current liabilities exceed current assets by over $250 million, and total liabilities exceed total assets by approximately $100 million, indicating a negative working capital position.
• Ongoing dental injury lawsuits related to SUBOXONE Film, with approximately 2,000 cases naming over 25,000 plaintiffs in the Dental MDL, posing significant potential liability.
• Primary insurance carrier issued a reservation of rights against payment of any liability costs for dental claims, increasing financial risk.
• Ongoing U.K. multiparty shareholder action related to an alleged product-hopping scheme.
• Ongoing False Claims Act allegations in United States ex rel. Miller v. Reckitt Benckiser Group PLC et al.
• Appeal pending in West Virginia NAS matters, adding to legal uncertainties.
• The FTC Order and State Attorneys General Settlement Order impose compliance and reporting obligations until November 2030.

Risks

• Heavy reliance on SUBLOCADE for a significant portion of revenues; any negative developments could materially affect financial results.
• Revenues may grow slower than expected or decrease due to competition, pricing pressure, payor policies, and adverse publicity.
• Reliance on third parties for manufacturing, packaging, testing, and distribution, subject to stringent regulatory requirements and potential disruptions.
• Failure to attain significant market acceptance for products.
• Substantial ongoing and future litigation (product liability, antitrust, shareholder claims, False Claims Act) could incur significant legal expenses and divert management attention.
• Need to comply with terms of FTC Stipulated Order and State Attorneys General Settlement Order until November 2030.
• Risks associated with importing, manufacturing, and distributing controlled substances, including stigma, misuse, diversion, and strict regulatory requirements (DEA, REMS).
• Acquisitions, partnerships, and strategic transactions involve inherent risks, including failure to realize anticipated benefits (e.g., OPVEE acquisition).
• Clinical or commercial use of products may cause unintended side effects or adverse reactions, leading to product liability claims or recalls.
• Dependence on third-party payors for reimbursement; reductions in reimbursement or increased cost-sharing could decrease sales.
• Potential cuts to Medicaid funding could impair access to products.
• Highly competitive industry with companies having greater resources.
• Failure to retain key personnel or attract new talent.
• Subject to various U.S. and international fraud, abuse, transparency, and privacy laws, with increased enforcement actions.
• Adverse public opinion due to the nature of OUD treatment and opioid-based products.
• Use of hazardous materials in manufacturing facilities poses environmental, health, and safety risks.
• Actual costs to exit various businesses may differ materially from estimates.
• Pipeline reliance on collaborations with third parties, with risks of failures to meet obligations or disputes.
• Clinical trials may be unsuccessful, and product candidates may not receive regulatory authorization.
• Failure to obtain and maintain patents and protect other proprietary rights.
• Substantial costs from intellectual property litigation.
• Regulatory agencies may impose limitations or post-approval requirements (labeling, REMS, post-marketing studies).
• Ongoing regulatory inspection and potential penalties for non-compliance.
• Changes in healthcare laws and regulations could adversely affect business.
• Guidelines from professional societies or other organizations may affect product use.
• Failure to comply with payment and reporting obligations under governmental pricing programs (Medicaid Drug Rebate, 340B).
• Failure to comply with anti-corruption, anti-money laundering, and economic sanctions laws.
• Increased government scrutiny on drug pricing and competition.
• Regulatory approval process is expensive, time-consuming, and uncertain.
• Leveraged balance sheet; reduction in revenue or changes in estimates may affect liquidity and profitability.
• Future transactions may dilute existing stockholders' interests or require additional funds.
• Effective tax rate may increase due to changes in tax laws or interpretations.
• Deferred tax assets may not be realized if sufficient taxable income is not generated.
• Tariffs on pharmaceutical products and reciprocal responses may affect revenues/profitability.
• Macroeconomic trends, geopolitics, and supply chain disruptions may affect sales and operations.
• Operating results may fluctuate significantly.
• Future pandemics may harm business.
• Insurance coverage may not be adequate, especially for opioid drug products.
• Term loan contains covenants that limit ability to plan for or respond to business changes.
• Common stock is subject to market price volatility.
• Securities or industry analysts' research can impact stock price.
• Parent company is a holding company dependent on subsidiaries for cash.
• May not pay dividends or repurchase shares in the future.
• Anti-takeover provisions in corporate documents and debt agreement.
• Business interruptions or data security breaches.
• Need to maintain privacy and security of personal information globally.
• Risks from artificial intelligence use.
• Exposure to currency exchange rates.
• Changes in accounting standards and subjective estimates.

Future Outlook

Indivior expects continued U.S. BMAT market growth in the mid-single-digit percentage range and anticipates continued LAI category growth with stable category share for SUBLOCADE in the U.S. However, total net revenue in 2026 is expected to decline compared to 2025 due to competitive pressures on SUBOXONE Film and strategic exits from certain non-U.S. markets. Research and development expenses are projected to be substantially lower than historic levels in 2026, with capital expenditures of $30 million to $40 million primarily for the Raleigh Manufacturing Facility.

Management Comments

• "Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease."
• "Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science."
• "Together with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope."
• "The Company continues to expect long-term U.S. BMAT market growth to remain within the mid-single-digit percentage range, reflecting public awareness of the opioid epidemic and approved treatments, as well as regulatory and legislative actions intended to expand access to BMAT therapies."
• "The Company expects to continue investing at sustained levels to support further LAI penetration by increasing patient awareness and advancing policies designed to improve patient access to treatment."
• "Prospectively, savings resulting from restructuring actions and discontinuation of sales and marketing of OPVEE will be used to support long-term SUBLOCADE growth."

Industry Context

StockSavvy.ai notes that Indivior operates in the highly competitive and regulated opioid use disorder (OUD) treatment market. The company's focus on long-acting injectables (LAIs) like SUBLOCADE aligns with a growing trend towards more convenient and adherence-friendly treatment options, especially given the high rates of relapse in OUD. The decline in SUBOXONE Film's market share due to generic competition is a common industry challenge for branded pharmaceuticals post-patent expiration. The strategic exits from certain Rest of World markets reflect a broader industry trend of companies streamlining operations to focus on core, profitable markets, particularly the lucrative U.S. market. The ongoing legal challenges, including product liability and antitrust claims, highlight the significant regulatory and litigation risks inherent in the pharmaceutical sector, particularly for companies dealing with controlled substances.

Comparison to Industry Standards

• Indivior's SUBLOCADE, as the primary long-acting injectable (LAI) for OUD, holds a mid-seventy percent share of the LAI segment, demonstrating strong market leadership compared to its main competitor, Camurus's BRIXADI (marketed as BUVIDAL outside the U.S.).
• The decline in SUBOXONE Film's category share from over 50% in 2018 to 14.2% in 2025 due to four generic competitors is typical for branded drugs facing generic erosion, comparable to the market dynamics seen with other major pharmaceutical products post-patent expiry.
• The company's gross margin of 80% in 2025 is generally healthy for a specialty pharmaceutical company, though slightly down from 81% in 2024, reflecting cost of sales factors including inventory write-downs for discontinued products.
• The R&D expense reduction from $107 million in 2024 to $97 million in 2025, with further substantial reductions expected in 2026, indicates a strategic shift towards a more focused pipeline, potentially below the R&D intensity of larger, diversified pharmaceutical companies but aligned with a specialty focus.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing lawsuits alleging SUBOXONE Film was defectively designed and caused dental injury, with approximately 2,000 cases naming over 25,000 plaintiffs consolidated in the Dental MDL.
• Proposed class actions in Quebec and British Columbia alleging dental injury from SUBOXONE Film and Tablets.
• Ongoing multiparty claims against Indivior PLC in the U.K. High Court alleging violations of the U.K. Financial Services and Markets Act 2000 (FSMA 2000) related to an alleged product-hopping scheme (SUBOXONE Tablets to SUBOXONE Film).
• Ongoing False Claims Act allegations in United States ex rel. Miller v. Reckitt Benckiser Group PLC et al.
• Appeal pending in West Virginia NAS matters.
• Settlement framework finalized for civil opioid litigation with states and subdivisions (State/Subdivision MSA) and Tribal Nations (Tribal MSA), with Year 1 funds transferred in January 2026.
• Agreement in principle reached with Maryland for a separate opioid settlement.
• FTC Order and State Attorneys General Settlement Order impose compliance and reporting obligations until November 2030.

Related Party Transactions

• Contract with RB (Reckitt Benckiser Group PLC), the former parent company, to manufacture SUBOXONE and SUBUTEX Tablets.
• Remaining $8 million liability related to an indemnity settlement with Reckitt Benckiser as of December 31, 2025.

Stakeholder Impact

• Shareholders: Positive impact from strong SUBLOCADE growth, increased profitability, and resolution of major litigation. Potential for future share price appreciation, but also dilution risk from future equity offerings.
• Patients (OUD): Improved access to SUBLOCADE due to label changes (rapid initiation, alternative injection sites) and continued investment in patient awareness and access policies. Discontinuation of OPVEE and PERSERIS may impact patients relying on those treatments.
• Healthcare Providers: More flexibility in administering SUBLOCADE. Continued education and support for OUD treatment.
• Employees: Restructuring of R&D and Medical Affairs organizations and optimization of Rest of World business led to headcount reductions. New hires in key leadership roles (CCO, EVP Corporate Affairs).
• Regulatory Authorities: Continued scrutiny and compliance obligations under FTC Order and State Attorneys General Settlement Order.
• Competitors: Increased competition for SUBOXONE Film from generics and for SUBLOCADE from BRIXADI.

Next Steps

• Announce results for INDV-6001 Phase 2 study in Q2 2026.
• Announce results for INDV-2000 Phase 2 study in Q2 2026.
• First case management conference for U.K. multiparty action set for July 23-24, 2026.
• Expected decrease in total operating expenses in 2026.
• Expected capital expenditures of $30 million to $40 million in 2026, primarily for Raleigh Manufacturing Facility.
• Continued investment to support further LAI penetration and patient access.
• Negotiate definitive documentation and implementation details for Maryland opioid settlement.
• Monitor ongoing private plaintiff cases in Opioid MDL and West Virginia NAS matters appeal.
• Monitor compliance with FTC Order and State Attorneys General Settlement Order until November 2030.
• Monitor False Claims Act allegations (United States ex rel. Miller v. Reckitt Benckiser Group PLC et al.).

Key Dates

Recommendation

Indivior's 2025 results demonstrate a strong turnaround in profitability, primarily driven by the robust growth of SUBLOCADE, which now constitutes the majority of its revenue. The resolution of significant past litigation and the U.S. domestication streamline operations and reduce major overhangs. While challenges remain with generic erosion of older products and ongoing legal matters, the company's focused strategy on its leading LAI OUD treatment, pipeline progress, and improved financial health suggest a positive trajectory for long-term investors. The current valuation may not fully reflect the de-risking from litigation settlements and the growth potential of SUBLOCADE.

Keywords

Indivior, Pharmaceuticals, Opioid Use Disorder, OUD, SUBLOCADE, SUBOXONE Film, Buprenorphine, Naloxone, SEC Filing, 10-K, Financial Report, Drug Development, Clinical Trials, Corporate Governance, Risk Management, Healthcare, Biopharmaceutical, Addiction Medicine, Generics, Regulatory Compliance, US Domestication